GlassScriptPhysician profile
Sassine Ghanem
NPI 1174905236
$1,936.70
in general payments reported to CMS, 2019-2025
15 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $655 · 2021: $252 · 2023: $21.31 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109 · Education: $21.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.02 |
| Education | $21.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $271.75 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $261.11 | 2020-2023 | Reblozyl |
| Exelixis INC. | $255.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $218.89 | 2019 | |
| Pfizer INC. | $181.90 | 2019-2021 | |
| Genentech USA, INC. | $172.80 | 2020-2025 | Venclexta |
| Genzyme Corporation | $138.34 | 2020-2021 | |
| Kite Pharma, INC. | $124.81 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $119.86 | 2019 | |
| Array Biopharma INC | $72.57 | 2020-2021 | |
| Tersera Therapeutics LLC | $30.01 | 2025 | Zoladex |
| Tesaro, INC. | $25.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.12 | 2025 | |
| Novocure INC. | $21.10 | 2025 | Optune Gio |
| Lilly USA, LLC | $17.22 | 2025 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sassine Ghanem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.